380 related articles for article (PubMed ID: 11156536)
1. High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency).
Grünewald S; Schollen E; Van Schaftingen E; Jaeken J; Matthijs G
Am J Hum Genet; 2001 Feb; 68(2):347-54. PubMed ID: 11156536
[TBL] [Abstract][Full Text] [Related]
2. Neurological presentation of a congenital disorder of glycosylation CDG-Ia: implications for diagnosis and genetic counseling.
Drouin-Garraud V; Belgrand M; Grünewald S; Seta N; Dacher JN; Hénocq A; Matthijs G; Cormier-Daire V; Frébourg T; Saugier-Veber P
Am J Med Genet; 2001 Jun; 101(1):46-9. PubMed ID: 11343337
[TBL] [Abstract][Full Text] [Related]
3. Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia.
Westphal V; Peterson S; Patterson M; Tournay A; Blumenthal A; Treacy EP; Freeze HH
Genet Med; 2001; 3(6):393-8. PubMed ID: 11715002
[TBL] [Abstract][Full Text] [Related]
4. Scandinavian CDG-Ia patients: genotype/phenotype correlation and geographic origin of founder mutations.
Erlandson A; Bjursell C; Stibler H; Kristiansson B; Wahlström J; Martinsson T
Hum Genet; 2001 May; 108(5):359-67. PubMed ID: 11409861
[TBL] [Abstract][Full Text] [Related]
5. A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency.
Westphal V; Kjaergaard S; Schollen E; Martens K; Grunewald S; Schwartz M; Matthijs G; Freeze HH
Hum Mol Genet; 2002 Mar; 11(5):599-604. PubMed ID: 11875054
[TBL] [Abstract][Full Text] [Related]
6. A deletion-insertion mutation in the phosphomannomutase 2 gene in an African American patient with congenital disorders of glycosylation-Ia.
Tayebi N; Andrews DQ; Park JK; Orvisky E; McReynolds J; Sidransky E; Krasnewich DM
Am J Med Genet; 2002 Mar; 108(3):241-6. PubMed ID: 11891694
[TBL] [Abstract][Full Text] [Related]
7. Cerebellar ataxia and congenital disorder of glycosylation Ia (CDG-Ia) with normal routine CDG screening.
Vermeer S; Kremer HP; Leijten QH; Scheffer H; Matthijs G; Wevers RA; Knoers NA; Morava E; Lefeber DJ
J Neurol; 2007 Oct; 254(10):1356-8. PubMed ID: 17694350
[TBL] [Abstract][Full Text] [Related]
8. Congenital disorder of glycosylation type Ia in a Malaysian family: clinical outcome and description of a novel PMM2 mutation.
Thong MK; Fietz M; Nicholls C; Lee MH; Asma O
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S41-4. PubMed ID: 19165618
[TBL] [Abstract][Full Text] [Related]
9. Mild clinical and biochemical phenotype in two patients with PMM2-CDG (congenital disorder of glycosylation Ia).
Casado M; O'Callaghan MM; Montero R; Pérez-Cerda C; Pérez B; Briones P; Quintana E; Muchart J; Aracil A; Pineda M; Artuch R
Cerebellum; 2012 Jun; 11(2):557-63. PubMed ID: 22012410
[TBL] [Abstract][Full Text] [Related]
10. Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG).
Thiesler CT; Cajic S; Hoffmann D; Thiel C; van Diepen L; Hennig R; Sgodda M; Weiβmann R; Reichl U; Steinemann D; Diekmann U; Huber NM; Oberbeck A; Cantz T; Kuss AW; Körner C; Schambach A; Rapp E; Buettner FF
Mol Cell Proteomics; 2016 Apr; 15(4):1435-52. PubMed ID: 26785728
[TBL] [Abstract][Full Text] [Related]
11. Phosphomannomutase activity in congenital disorders of glycosylation type Ia determined by direct analysis of the interconversion of mannose-1-phosphate to mannose-6-phosphate by high-pH anion-exchange chromatography with pulsed amperometric detection.
Orvisky E; Stubblefield B; Long RT; Martin BM; Sidransky E; Krasnewich D
Anal Biochem; 2003 Jun; 317(1):12-8. PubMed ID: 12729595
[TBL] [Abstract][Full Text] [Related]
12. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.
Schiff M; Roda C; Monin ML; Arion A; Barth M; Bednarek N; Bidet M; Bloch C; Boddaert N; Borgel D; Brassier A; Brice A; Bruneel A; Buissonnière R; Chabrol B; Chevalier MC; Cormier-Daire V; De Barace C; De Maistre E; De Saint-Martin A; Dorison N; Drouin-Garraud V; Dupré T; Echenne B; Edery P; Feillet F; Fontan I; Francannet C; Labarthe F; Gitiaux C; Héron D; Hully M; Lamoureux S; Martin-Coignard D; Mignot C; Morin G; Pascreau T; Pincemaille O; Polak M; Roubertie A; Thauvin-Robinet C; Toutain A; Viot G; Vuillaumier-Barrot S; Seta N; De Lonlay P
J Med Genet; 2017 Dec; 54(12):843-851. PubMed ID: 28954837
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations.
Vega AI; Pérez-Cerdá C; Abia D; Gámez A; Briones P; Artuch R; Desviat LR; Ugarte M; Pérez B
J Inherit Metab Dis; 2011 Aug; 34(4):929-39. PubMed ID: 21541725
[TBL] [Abstract][Full Text] [Related]
14. Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype).
Barone R; Sturiale L; Fiumara A; Uziel G; Garozzo D; Jaeken J
J Inherit Metab Dis; 2007 Feb; 30(1):107. PubMed ID: 17186415
[TBL] [Abstract][Full Text] [Related]
15. A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency.
Cline A; Gao N; Flanagan-Steet H; Sharma V; Rosa S; Sonon R; Azadi P; Sadler KC; Freeze HH; Lehrman MA; Steet R
Mol Biol Cell; 2012 Nov; 23(21):4175-87. PubMed ID: 22956764
[TBL] [Abstract][Full Text] [Related]
16. Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.
Sharma V; Ichikawa M; He P; Scott DA; Bravo Y; Dahl R; Ng BG; Cosford ND; Freeze HH
J Biol Chem; 2011 Nov; 286(45):39431-8. PubMed ID: 21949237
[TBL] [Abstract][Full Text] [Related]
17. Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.
Serrano M; de Diego V; Muchart J; Cuadras D; Felipe A; Macaya A; Velázquez R; Poo MP; Fons C; O'Callaghan MM; García-Cazorla A; Boix C; Robles B; Carratalá F; Girós M; Briones P; Gort L; Artuch R; Pérez-Cerdá C; Jaeken J; Pérez B; Pérez-Dueñas B
Orphanet J Rare Dis; 2015 Oct; 10():138. PubMed ID: 26502900
[TBL] [Abstract][Full Text] [Related]
18. The Effects of PMM2-CDG-Causing Mutations on the Folding, Activity, and Stability of the PMM2 Protein.
Yuste-Checa P; Gámez A; Brasil S; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
Hum Mutat; 2015 Sep; 36(9):851-60. PubMed ID: 26014514
[TBL] [Abstract][Full Text] [Related]
19. Genotypes and estimated prevalence of phosphomannomutase 2 deficiency in Turkey differ significantly from those in Europe.
Yıldız Y; Arslan M; Çelik G; Kasapkara ÇS; Ceylaner S; Dursun A; Sivri HS; Coşkun T; Tokatlı A
Am J Med Genet A; 2020 Apr; 182(4):705-712. PubMed ID: 31981409
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of novel mutations in a congenital disorder of glycosylation Ia patient with mixed Asian ancestry.
Westphal V; Enns GM; McCracken MF; Freeze HH
Mol Genet Metab; 2001 May; 73(1):71-6. PubMed ID: 11350185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
